You are here: Industry Insights > Merck KGaA

News List

Merck KGaA signs deal with Artios Pharma for cancer drugs research expresspharma
December 07, 2020
Artios will receive $30 million in up-front and near-term payments, plus double-digit option fees and up $860 million total milestones per target.
Merck KGaA, IAVI and Serum Institute link up to develop COVID-19 mAbs pharmatimes
October 26, 2020
German pharma company Merck KGaA has partnered with non-profit scientific research organisation IAVI and Serum Institute of India to develop monoclonal antibodies (mAbs) for COVID-19.
IAVI, Merck KGaA and Serum Institute partner to develop COVID-19 mAbs expresspharma
October 23, 2020
The partnership aims to ensure access to a class of innovative therapies that have, to date, been out of reach in low- and middle-income countries (LMICs).
Merck KGaA, Darmstadt, AMCM Cooperate in 3D Printing of Tablets americanpharmaceuticalreview
March 05, 2020
Merck KGaA, Darmstadt, Germany and AMCM, Starnberg, Germany, announced a cooperation agreement on the 3D printing of tablets.
Genome & Company announces a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer prnasia
January 15, 2020
Genome & Company (KONEX: 314130) is pleased to announce that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to evaluate the safety, tolerability, biological and clinical activit
GSK poaches Merck KGaA exec to replace departing U.S. pharma president Bailey fiercepharma
August 14, 2019
GlaxoSmithKline has seen plenty of changes across its executive ranks over the last couple of years as CEO Emma Walmsley took the helm, but they’re still coming.
Better 8 years late than never: Merck KGaA nabs FDA nod for MS drug Mavenclad fiercepharma
April 02, 2019
Up to 10 years of safety data has paid off for Merck KGaA’s oral multiple sclerosis treatment Mavenclad.
Pfizer, Merck KGaA scrap yet another Bavencio ovarian cancer trial fiercepharma
March 21, 2019
Pfizer and Merck KGaA have had a rough go at broadening immuno-oncology drug Bavencio's reach……
Merck KGaA, Pfizer added to BioXcel’s pancreatic cancer deal pharmatimes
March 06, 2019
BioXcel Therapeutics has announced the addition of Merck KGaA and Pfizer to clinical collaboration with Nektar Therapeutics, to evaluate a novel triple combination therapy in pancreatic cancer.
Merck KGaA signs China digital health deal with Tencent pharmaphorum
January 25, 2019
Germany’s Merck KGaA has signed a collaboration with Tencent to develop digital healthcare services in China.

Previous page 1 2 3 4 Next page